PROKARIUM
7.2.2024 13:01:36 CET | Business Wire | Press release
Prokarium, a clinical-stage biopharmaceutical company bioengineering Living Cures through cutting-edge synthetic biology, today announces the dosing of the first patient in their PARADIGM-1 Phase I/Ib clinical trial in non-muscle invasive bladder cancer (NMIBC) patients (NCT06181266).
The study is being conducted at multiple clinical sites across the United States and will initially evaluate the safety of a single intravesical administration of their investigational immunotherapy, ZH9, in NMIBC patients. The study will further investigate and characterize clinical efficacy of the ZH9 treatment regimen in pre-planned expansion cohorts under the same IND.
“Dosing our first patient in the clinical trial is an exciting milestone,” said Dr. Josefin-Beate (Josi) Holz, CMO of Prokarium. “It translates our scientific promises into practical advancements, as we strive to transform the treatment paradigm for patients with NMIBC.”
Dr. Daniel Zainfeld, Urology San Antonio, commented, “We are excited to have dosed our first patient in Prokarium’s PARADIGM-1 study. The trial provides us the opportunity to explore an innovative treatment approach for our NMIBC patients who are facing significant gaps in available effective treatment options.”
Kristen Albright, CEO of Prokarium, remarked, "We are grateful to the patients and urologists involved in the PARADIGM-1 clinical trial. This achievement represents a pivotal moment for Prokarium as we introduce Living Cures, a novel class of immunotherapies built with synthetic biology.”
About Prokarium
Prokarium is a clinical-stage biopharmaceutical company bioengineering Living Cures through cutting-edge synthetic biology. Prokarium’s lead program, currently advancing in US clinical trials for bladder cancer, is a single-dose therapy redesigning the treatment paradigm for patients. The Company’s Living Cures platform aims to transform precision medicine into off-the-shelf programmable therapeutics, promising a new class of immunotherapies with a goal of equitable access. Prokarium is based in London, UK. For further information, visit https://www.prokarium.com.
About ZH9
ZH9, a proprietary bacterial immunotherapy under investigation in the PARADIGM-1 clinical trial (NCT06181266) in the United States, seeks to redesign the treatment paradigm for non-muscle invasive bladder cancer patients through a single-dose intravesical induction regimen.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240207504370/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barnes Molding Solutions Becomes SPECTRIX21.4.2026 07:00:00 CEST | Press release
Barnes Molding Solutions is now SPECTRIX. The new Brand offers the full Spectrum of injection molding capabilities delivered by its leading brands - Männer, Foboha, Synventive, Priamus, Thermoplay, and Gammaflux. The change, announced at Chinaplas 2026, reflects the integration of core technologies within a single organization: part design, material science, hot runner and mold technology, sensors & controls and injection molding. Day-to-day operations remain unchanged, including contacts, contracts, and processes. Focused on global growth Under President Marcello Vendemiati, SPECTRIX is strengthening its global market focus and expanding its footprint. This strategy is already visible with the opening of a new manufacturing facility in Pune, India. Another production site near Detroit, USA, is set to open soon. The name SPECTRIX combines “spectrum” and “plastics,” while reflecting the company’s core strengths: expertise, experience, and excellence. Its tagline, “Enduring Advantage, En
Bringg Welcomes Chris Conway as Senior Vice President and General Manager, EMEA21.4.2026 07:00:00 CEST | Press release
Conway, who scaled one of the UK’s largest delivery operations as a Bringg customer, joins to lead the company’s European expansion Bringg, the last-mile performance leader, today announced Chris Conway's appointment as Senior Vice President and General Manager, EMEA. Conway will lead Bringg's commercial strategy, customer relationships, and go-to-market operations across the region. Conway brings more than 20 years of experience in eCommerce, digital commerce, and operational transformation at three of the UK's largest grocery retailers. Most recently, he served as Managing Director of Quick Commerce and Food Operating Board Member at Co-op, where he built and scaled a £500 million-plus q-commerce operation delivering from nearly 2,000 stores. He also founded Peckish, a rapid delivery app that gave independent retailers access to q-commerce technology. He also led Asda's online grocery business to more than £1 billion in revenue and 20% market share, and ran the online commercial team
Edge Home Finance Announces Strategic Investment from Presidio Investors and Promotion of Tom Ahles to President21.4.2026 06:06:00 CEST | Press release
Edge Home Finance today announced a strategic investment from Presidio Investors (“Presidio”), marking a major milestone in the company’s continued expansion and leadership within the mortgage broker channel. As part of this transaction, Tom Ahles has been promoted to President of Edge Home Finance, reinforcing the company’s commitment to strong leadership as it enters its next phase of growth. The investment from Presidio represents a powerful alignment focused on accelerating Edge’s momentum through enhanced investment in technology, operational infrastructure, and strategic acquisitions. Presidio brings a track record of partnering with high-growth companies and scaling them through disciplined capital deployment and operational expertise. “This strategic investment is a direct reflection of the strength of our platform and the momentum we’ve built,” said Tom Ahles, President of Edge Home Finance. “With Presidio’s backing, we are positioned to move faster, invest more aggressively i
JPMorganChase Expands Security and Resiliency Initiative Across Europe21.4.2026 06:00:00 CEST | Press release
Broader geographic focus builds on momentum in the U.S. and reinforces commitment to strengthening critical supply chains, economic resilience and shared security across trading partners JPMorganChase today announced the expansion of its $1.5 trillion, 10-year Security and Resiliency Initiative (SRI) — which seeks to facilitate, finance and invest in industries vital to economic security — across Europe. Building on the initiative’s momentum in the U.S. and previously announced intention to expand to the U.K., the announcement underscores JPMorganChase’s commitment to strengthening supply chains and supporting industries critical to innovation and growth. “The national and economic security of countries depends on strong, resilient and reliable supply chains, and robust critical industries,” said Jamie Dimon, Chairman and CEO of JPMorganChase. “For too long, the U.S. and Europe have relied on unpredictable sources for things like critical minerals that are essential to collective secur
Presidio Investors Expands Portfolio with Strategic Investment in Edge Home Finance21.4.2026 03:10:00 CEST | Press release
Presidio Investors ("Presidio") has completed a strategic investment in Edge Home Finance, a mortgage brokerage platform. Headquartered in Minnetonka, MN, Edge Home Finance has built a strong reputation within the mortgage broker channel by empowering loan originators and delivering best-in-class service and innovation. The investment from Presidio represents an opportunity to leverage Edge’s momentum through enhanced investments in technology, operational infrastructure, and strategic acquisitions. Edge Home Finance will continue operating with the same core platform, team, and commitment to the broker community that has fueled its success. Partner, Victor Masaya, of Presidio Investors, commented: “Edge Home Finance's platform, track record and broker-focused approach aligns perfectly with our vision of fostering excellence and growth. Together, we aim to redefine what's possible in the mortgage brokerage channel and deliver an unparalleled value proposition to loan originators." Edge
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom